HIV integrase inhibitors
View Patent ↗Hydroxy (tetra- or hexa-)hydronaphthyridine dione compounds of Formula I are inhibitors of HIV integrase and inhibitors of HIV replication: (I) wherein a, R 1?, R 2?, R 3?, R 4? and R 5? are defined herein. The compounds are useful in the prevention and treatment of infection by HIV and in the prevention, delay in the onset, and treatment of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.
1. A compound of Formula I, or a pharmaceutically acceptable salt thereof:
wherein:
bond
in the ring is a single bond or a double bond;
R 1 is —C 1-6 alkyl substituted with R J , wherein R J is:
(A) (i) aryl or (ii) aryl fused to a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein the aryl or fused aryl is:
(a) optionally substituted with from 1 to 5 substituents each of which is independently:
(1) —C 1-6 alkyl optionally substituted with —OH, —O—C 1-6 alkyl, —O—C 1-6 haloalkyl, —CN, —NO 2 , —N(R a )R b , —C(═O)N(R a )R b , —C(═O)R a , —CO 2 R a , —S(O) n R a , —SO 2 N(R a )R b , —N(R a )C(═O)R b , —N(R a )CO 2 R b , —N(R a )SO 2 R b , —N(R a )SO 2 N(R a )R b , —OC(═O)N(R a )R b , or —N(R a )C(═O)N(R a )R b ,
(2) —O—C 1-6 alkyl,
(3) —C 1-6 haloalkyl,
(4) —O—C 1-6 haloalkyl,
(5) —OH,
(6) halogen,
(7) —CN,
(8) —NO 2 ,
(9) —N(R a )R b ,
(10) —C(═O)N(R a )R b ,
(11) —C(═O)R a ,
(12) —CO 2 R a ,
(13) —SR a ,
(14) —S(═O)R a ,
(15) —SO 2 R a ,
(16) —SO 2 N(R a )R b ,
(17) —N(R a )SO 2 R b ,
(18) —N(R a )SO 2 N(R a )R b ,
(19) —N(R a )C(═O)R b ,
(20) —N(R a )C(═O)—C(═O)N(R a )R b , or
(21) —N(R a )CO 2 R b , and
(b) optionally substituted with 1 or 2 substituents each of which is independently:
(1) phenyl,
(2) benzyl,
(3) —HetA,
(4) —C(═O)—HetA, or
(5) —HetB;
wherein each HetA is independently a C 4-7 azacycloalkyl or a C 3-6 diazacycloalkyl, either of which is optionally substituted with from 1 to 4 substituents each of which is independently oxo or C 1-6 alkyl; and
wherein each HetB is independently a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein the heteroaromatic ring is optionally substituted with from 1 to 4 substituents each of which is independently halogen, C 1-6 alkyl, C 1-6 haloalkyl, O—C 1-6 alkyl, O—C 1-6 haloalkyl, or hydroxy; or
(B) a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein the heteroaromatic ring is:
(i) optionally substituted with from 1 to 4 substituents each of which is independently halogen, —C 1-6 alkyl, —C 1-6 haloalkyl, —O—C 1-6 alkyl, —O—C 1-6 haloalkyl, or hydroxy; and
(ii) optionally substituted with 1 or 2 substituents each of which is independently aryl or —C 1-6 alkyl substituted with aryl;
R 2 and R 3 are each independently —H or —C 1-6 alkyl;
R 4 is:
(1) —H,
(2) —C 1-6 alkyl,
(3) —C 1-6 haloalkyl,
(4) —C 1-6 alkyl substituted with —OH, —O—C 1-6 alkyl, —O—C 1-6 haloalkyl, —CN, —N(R a )R b , —C(═O)N(R a )R b , —C(═O)R a , —CO 2 R a , —C(═O)—N(R a )—C 1-6 alkylene-OR b with the proviso that the —N(R a )— moiety and the —OR b moiety are not both attached to the same carbon of the —C 1-6 alkylene-moiety, —S(O) n R a , —SO 2 N(R a )R b , —N(R a )C(═O)—R b , —N(R a )CO 2 R b , —N(R a )SO 2 R b , —N(R a )SO 2 N(R a )R b , —N(R a )C(═O)N(R a )R b , or —OC(═O)N(R a )R b ,
(5) —C(═O)R a ,
(6) —CO 2 R a ,
(7) —C(═O)N(R a )R b ,
(8) —C(═O)—N(R a )—C 1-6 alkylene-OR b with the proviso that the —N(R a )— moiety and the —OR b moiety are not both attached to the same carbon of the —C 1-6 alkylene-moiety,
(9) —N(R a )—C(═O)—R b ,
(10) —N(R a )—C(═O)—C(═O)N(R a )R b ,
(11) —N(R a )SO 2 R b ,
(12) —N(R a )SO 2 N(R a )R b ,
(13) —N(R a )C(═O)N(R a )R b ,
(14) —OC(═O)N(R a )R b ,
(15) —R K ,
(16) —C(═O)—R K ,
(17) —C(═O)N(R a )—R K ,
(18) —C(═O)N(R a )—C 1-6 alkylene-R K ,
(19) —C 1-6 alkyl substituted with —R K ,
(20) —C 1-6 alkyl substituted with —C(═O)—R K ,
(21) —C 1-6 alkyl substituted with —C(═O)N(R a )—R K , or
(22) —C 1-6 alkyl substituted with —C(═O)N(R a )—C 1-6 alkylene-R K ,
wherein R K is
(i) C 3-8 cycloalkyl which is optionally substituted with from 1 to 4 substituents each of which is independently halogen, —OH, —C 1-6 alkyl, —C 1-6 haloalkyl, —O—C 1-6 alkyl, or —O—C 1-6 haloalkyl,
(ii) aryl, which is optionally substituted with from 1 to 5 substituents each of which is independently —C 1-6 alkyl, —C 1-6 alkylene-OH, —C 1-6 alkylene-O—C 1-6 alkyl, —C 1-6 alkylene-O—C 1-6 haloalkyl, —C 1-6 alkylene-N(R a )R b , —C 1-6 alkylene-C(═O)N(R a )R b , —C 1-6 alkylene-C(═O)R a , —C 1-6 alkylene-CO 2 R a , —C 1-6 alkylene-S(O) n R a , —O—C 1-6 alkyl, —C 1-6 haloalkyl, —O—C 1-6 haloalkyl, —OH, halogen, —N(R a )R b , —C(═O)N(R a )R b , —C(═O)R a , —CO 2 R a , —S(O) n R a , or —SO 2 N(R a )R b ,
(iii) HetK, which is a 4- to 7-membered saturated heterocyclic ring containing at least one carbon atom and from 1 to 4 heteroatoms independently selected from N, O and S, wherein the heterocyclic ring is:
(a) optionally substituted with from 1 to 6 substituents each of which is independently halogen, —C 1-6 alkyl, —C 1-6 haloalkyl, —O—C 1-6 alkyl, —O—C 1-6 haloalkyl, oxo; and
(b) optionally substituted with aryl or HetC;
wherein HetC is a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein the heteroaromatic ring is optionally fused with a benzene ring, and the optionally fused heteroaromatic ring is optionally substituted with from 1 to 4 substituents each of which is independently —C 1-6 alkyl, —C 1-6 haloalkyl, —O—C 1-6 alkyl, —O—C 1-6 haloalkyl, or hydroxy; or
(iv) —HetL, which is a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein the heteroaromatic ring is optionally substituted with from 1 to 4 substituents each of which is independently halogen, —C 1-6 alkyl, —C 1-6 haloalkyl, —O—C 1-6 alkyl, —O—C 1-6 haloalkyl, or hydroxy;
R 5 is:
(1) —H,
(2) —C 1-6 alkyl,
(3) —C 3-8 cycloalkyl optionally substituted with from 1 to 4 substituents each of which is independently halogen,—OH, C 1-6 alkyl, —C 1-6 haloalkyl, —O—C 1-6 alkyl, —O—C 1-6 haloalkyl,
(4) —C 1-6 alkyl substituted with C 3-8 cycloalkyl, wherein the cycloalkyl is optionally substituted with from 1 to 4 substituents each of which is independently halogen, —OH, —C 1-6 alkyl, —C 1-6 haloalkyl, —O—C 1-6 alkyl, or —O—C 1-6 haloalkyl,
(5) —C 1-6 alkyl substituted with aryl, wherein the aryl is optionally substituted with from 1 to 5 substituents each of which is independently —C 1-6 alkyl, —C 1-6 alkylene-OH, —C 1-6 alkylene- O—C 1-6 alkyl, —C 1-6 alkylene-O—C 1-6 haloalkyl, —C 1-6 alkylene-N(R a )R b , —C 1-6 alkylene-C(═O)N(R a )R b , —C 1-6 alkylene-C(═O)R a , —C 1-6 alkylene-CO 2 R a , —C 1-6 alkylene-S(O) n R a , —O—C 1-6 alkyl, —C 1-6 haloalkyl, —O—C 1-6 haloalkyl, —OH, halogen, —N(R a )R b , —C(═O)N(R a )R b , —C(═O)R a , —CO 2 R a , —S(O) n R a , or —SO 2 N(R a )R b , or
(6) —C 1-6 alkyl substituted with HetD, wherein HetD is:
(i) a 4- to 7-membered saturated heterocyclic ring containing at least one carbon atom and from 1 to 4 heteroatoms independently selected from N, O and S, wherein the heterocyclic ring is optionally substituted with from 1 to 5 substituents each of which is independently halogen, —C 1-6 alkyl, —C 1-6 haloalkyl, —O—C 1-6 alkyl, —O—C 1-6 haloalkyl, or oxo; or
(ii) a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein the heteroaromatic ring is optionally substituted with from 1 to 4 substituents each of which is independently —C 1-6 alkyl, —C 1-6 haloalkyl, —O—C 1-6 alkyl, —O—C 1-6 haloalkyl, or hydroxy;
each aryl is independently phenyl, naphthyl, or indenyl;
each R a is independently H or C 1-6 alkyl;
each R b is independently H or C 1-6 alkyl; and
each n is independently an integer equal to zero, 1, or 2.
2. A compound according to claim 1 which is a compound of Formula II, or a pharmaceutically acceptable salt thereof:
wherein:
X 1 and X 2 are each independently:
(1) —H,
(2) —C 1-6 alkyl,
(3) —O—C 1-6 alkyl,
(4) —C 1-6 haloalkyl,
(5) —O—C 1-6 haloalkyl,
(6) halogen,
(7) —CN,
(8) —N(R a )R b ,
(9) —C(═O)N(R a )R b ,
(10) —SR a ,
(11) —S(O)R a ,
(12) —SO 2 R a ,
(13) —N(R a )SO 2 R b ,
(14) —N(R a )SO 2 N(R a )R b ,
(15) —N(R a )C(═O)R b ,
(16) —N(R a )C(═O)—C(═O)N(R a )R b ,
(17) —HetA,
(18) —C(═O)—HetA, or
(19) HetB;
wherein each HetA is independently a C 4-5 azacycloalkyl or a C 3-4 diazacycloalkyl, either of which is optionally substituted with 1 or 2 substituents each of which is independently oxo or C 1-6 alkyl; and with the proviso that when HetA is attached to the rest of the compound via the —C(═O)— moiety, the HetA is attached to the —C(═O)— via a ring N atom; and
each HetB is independently a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein the heteroaromatic ring is optionally substituted with from 1 to 4 substituents each of which is independently halogen, —C 1-6 alkyl, —C 1-6 haloalkyl, —O—C 1-6 alkyl, —O—C 1-6 haloalkyl, or hydroxy;
R 4 is:
(1) —CO 2 R a ,
(2) —C(═O)N(R a )R b ,
(3) —C(═O)—N(R a )—(CH 2 ) 2-3 —OR b ,
(4) —N(R a )C(═O)R b ,
(5) —N(R a )SO 2 R b ,
(6) —HetK,
(7) —C(═O)—HetK,
(8) —C(═O)N(R a )—(CH 2 ) 0-2 —(C 3-6 cycloalkyl), wherein the cycloalkyl is optionally substituted with from 1 to 4 substituents each of which is independently halogen, —C 1-6 alkyl, —CF 3 , —O—C 1-6 alkyl, or —OCF 3 , or
(9) —C(═O)N(R a )—CH 2 -phenyl, wherein the phenyl is optionally substituted with from 1 to 4 substituents each of which is independently —C 1-6 alkyl, —O—C 1-6 alkyl, —CF 3 , —OCF 3 , or halogen;
wherein HetK is a 5- or 6-membered saturated heterocyclic ring containing a total of from 1 to 4 heteroatoms independently selected from 1 to 4 N atoms, from 0 to 2 O atoms, and from 0 to 2 S atoms, wherein the heterocyclic ring is optionally substituted with (i) from 1 to 4 substituents each of which is independently —C 1-6 alkyl, oxo; and with the proviso that when HetK is attached to the rest of the compound via the —C(═O)— moiety, the HetK is attached to the —C(═O)— via a ring N atom;
R 5 is:
(1) —H,
(2) —C 1-6 alkyl,
(3) —C 3-6 cycloalkyl,
(4) —(CH 2 ) 1-2 —C 3-6 cycloalkyl, or
(5) —CH 2 -phenyl;
each R a is independently H or C 1-6 alkyl; and
each R b is independently H or C 1-6 .
3. The compound according to claim 2 , or a pharmaceutically acceptable salt thereof, wherein:
X 1 and X 2 are each independently:
(1) —H,
(2) —C 1-4 alkyl,
(3) —C 1-4 haloalkyl,
(4) —O—C 1-4 alkyl,
(5) halogen,
(6) —CN,
(7) —C(═O)NH 2 ,
(8) —C(═O)NH(—C 1-4 alkyl),
(9) —C(═O)N(—C 1-4 alkyl) 2 , or
(10) —SO 2 —C 1-4 alkyl;
R 4 is:
(1) —CO 2 H,
(2) —C(═O)—O—C 1-4 alkyl,
(3) —C(═O)NH 2 ,
(4) —C(═O)NH—C 1-4 alkyl,
(5) —C(═O)N(C 1-4 alkyl) 2 ,
(6) —C(═O)—NH—(CH 2 ) 2-3 —O—C 1-4 alkyl,
(7) —C(═O)—N(C 1-4 alkyl)—(CH 2 ) 2-3 —O—C 1-4 alkyl,
(8) —NHC(═O)—C 1-4 alkyl,
(9) —N(C 1-4 alkyl)C(═O)—C 1-4 alkyl,
(10) —NHSO 2 —C 1-4 alkyl,
(11) —N(C 1-4 alkyl)SO 2 —C 1-4 alkyl,
(12) —C(═O)—HetK, wherein HetK is:
wherein the asterisk * denotes the point of attachment to the rest of the compound,
(13) —C(═O)NH—(CH 2 ) 0-1 —(C 3-6 cycloalkyl),
(14) —C(═O)N(C 1-4 alkyl)-(CH 2 ) 0-1 —(C 3-6 cycloalkyl),
(15) —C(═O)NH—CH 2 -phenyl, or
(16) —C(═O)N(C 1-4 alkyl)-CH 2 -phenyl; and
R 5 is:
(1) —H,
(2) —C 1-4 alkyl,
(3) —C 3-6 cycloalkyl, or
(4) —CH 2 —C 3-6 cycloalkyl, or
(5) —CH 2 -phenyl.
4. The compound according to claim 2 , or a pharmaceutically acceptable salt thereof, which is a compound of Formula III:
wherein:
X 1 is:
(1) —H,
(2) bromo,
(3) chloro,
(4) fluoro, or
(5) methoxy;
X 2 is:
(1) —H,
(2) bromo,
(3) chloro,
(4) fluoro,
(5) methoxy,
(6) —C 1-4 alkyl,
(7) —CF 3 ,
(8) —OCF 3 ,
(9) —CN, or
(10) —SO 2 (C 1-4 alkyl);
R 4 is:
(1) —CO 2 H,
(2) —C(═O)—O—C 1-4 alkyl,
(3) —C(═O)NH 2 ,
(4) —C(═O)NH—C 1-4 alkyl,
(5) —C(═O)N(C 1-4 alkyl) 2 ,
(6) —C(═O)—NH—(CH 2 ) 2-3 —O—C 1-4 alkyl,
(7) —C(═O)—N(C 1-4 alkyl)-(CH 2 ) 2-3 —O—C 1-4 alkyl,
(8) —NHC(═O)—C 1-4 alkyl,
(9) —N(C 1-4 alkyl)C(═O)—C 1-4 alkyl,
(10) —NHSO 2 —C 1-4 alkyl,
(11) —N(C 1-4 alkyl)SO 2 —C 1-4 alkyl,
(12) —C(═O)—HetK, wherein HetK is:
wherein the asterisk * denotes the point of attachment to the rest of the compound,
(13) —C(═O)NH—(CH 2 ) 0-1 —(C 3-6 cycloalkyl),
(14) —C(═O)N(C 1-4 alkyl)-(CH 2 ) 0-1 —(C 3-6 cycloalkyl),
(15) —C(═O)NH—CH 2 -phenyl, or
(16) —C(═O)N(C 1-4 alkyl)-CH 2 -phenyl; and
R 5 is:
(1) —H,
(2) —C 1-4 alkyl,
(3) cyclopropyl,
(4) cyclobutyl,
(5) —CH 2 -cyclopropyl,
(6) —CH 2 -cyclobutyl, or
(7) —CH 2 -phenyl.
5. A pharmaceutical composition comprising an effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
6. A method for treating infection by HIV or for treating AIDS in a subject in need thereof which comprises administering to the subject an effective amount of the compound according to claim 1 , or a pharmaceutically acceptable salt thereof.
7. A process for preparing a compound of Formula IV:
which comprises:
(B) contacting a compound of Formula V:
with a Grignard salt of an amine of Formula VI:
HN(R V )R W (VI)
to obtain Compound IV; wherein:
bond
in the ring is a single bond or a double bond;
R 1 is —C 1-6 alkyl substituted with R J , wherein R J is:
(A) aryl or aryl fused to a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein the aryl or fused aryl is:
(a) optionally substituted with from 1 to 5 substituents each of which is independently:
(1) —C 1-6 alkyl,
(2) —C 1-6 alkyl substituted with —O—C 1-6 alkyl, —O—C 1-6 haloalkyl, —NO 2 , —N(R a )R b , or —S(O) n R a ,
(3) —C 1-6 haloalkyl,
(4) —O—C 1-6 alkyl,
(5) halogen,
(6) C(═O)N(R a )R b , or
(7) —SO 2 R a , and
(b) optionally substituted with 1 or 2 substituents each of which is independently:
(1) phenyl,
(2) benzyl, or
(3) -HetB;
wherein each HetB is a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein the heteroaromatic ring is optionally substituted with from 1 to 4 substituents each of which is independently halogen, —C 1-6 alkyl, —C 1-6 haloalkyl, —O—C 1-6 alkyl, or —O—C 1-6 haloalkyl; or
(B) a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S; wherein the heteroaromatic ring is
(i) optionally substituted with from 1 to 4 substituents each of which is independently halogen, —C 1-6 alkyl, —C 1-6 haloalkyl, —O—C 1-6 alkyl, or —O—C 1-6 haloalkyl, and
(ii) optionally substituted with 1 or 2 substituents each of which is independently aryl or —C 1-6 alkyl substituted with aryl;
R 2 and R 3 are each independently —H or —C 1-6 alkyl;
R 5 is:
(1) —C 1-6 alkyl,
(2) —C 3-8 cycloalkyl optionally substituted with from 1 to 4 substituents each of which is independently —C 1-6 alkyl or —O—C 1-6 alkyl,
(3) —C 1-6 alkyl substituted with C 3-8 cycloalkyl, wherein the cycloalkyl is optionally substituted with from 1 to 4 substituents each of which is independently —C 1-6 alkyl or —O—C 1-6 alkyl,
(4) —C 1-6 alkyl substituted with aryl, wherein the aryl is optionally substituted with from 1 to 5 substituents each of which is independently —C 1-6 alkyl, —C 1-6 alkylene-O—C 1-6 alkyl, or halogen, or
(5) —C 1-6 alkyl substituted with a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein the heteroaromatic ring is optionally substituted with from 1 to 4 substituents each of which is independently —C 1-6 alkyl;
R T is —C 1-6 alkyl;
R V and R W are each independently —C 1-6 alkyl or R V and R W together with the N atom to which they are both attached form a 4- to 6-membered saturated heterocyclic ring optionally containing a heteroatom in addition to the nitrogen attached to R V and R W selected from N, O, and S, where the S is optionally oxidized to S(O) or S(O) 2 , and wherein the saturated heterocyclic ring is optionally substituted with 1 or 2 substituents each of which is independently a C 1-6 alkyl group;
each aryl is independently phenyl, naphthyl, or indenyl;
each R a is independently H or C 1-6 alkyl; and
each R b is independently H or C 1-6 alkyl.
8. The process according to claim 7 , wherein the process further comprises:
(A) treating a compound of Formula IX:
with (i) a tertiary amine base in the presence of a lithium salt or (ii) an alkoxide base, to obtain a compound of Formula V; wherein one of bonds
and
is a single bond and the other is a double bond; and R T * is C 1-6 alkyl.
9. A process for preparing a compound of Formula IV:
which comprises treating a compound of Formula X:
with (i) a tertiary amine base in the presence of a lithium salt or (ii) an alkoxide base, to obtain a compound of Formula IV, wherein:
bond
in the ring is a single bond or a double bond;
R 1 is —C 1-6 alkyl substituted with R J , wherein R J is:
(A) aryl or aryl fused to a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein the aryl or fused aryl is:
(a) optionally substituted with from 1 to 5 substituents each of which is independently:
(1) —C 1-6 alkyl,
(2) —C 1-6 alkyl substituted with —O—C 1-6 alkyl, —O—C 1-6 haloalkyl, —NO 2 , —N(R a )R b , or —S(O) n R a ,
(3) —C 1-6 haloalkyl,
(4) —O—C 1-6 alkyl,
(5) halogen,
(6) C(═O)N(R a )R b , or
(7) —SO 2 R a , and
(b) optionally substituted with 1 or 2 substituents each of which is independently:
(1) phenyl,
(2) benzyl, or
(3) -HetB;
wherein each HetB is a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein the heteroaromatic ring is optionally substituted with from 1 to 4 substituents each of which is independently halogen, —C 1-6 alkyl, —C 1-6 haloalkyl, —O—C 1-6 alkyl, or —O—C 1-6 haloalkyl; or
(B) a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S; wherein the heteroaromatic ring is
(i) optionally substituted with from 1 to 4 substituents each of which is independently halogen, —C 1-6 alkyl, —C 1-6 haloalkyl, —O—C 1-6 alkyl, or —O—C 1-6 haloalkyl, and
(ii) optionally substituted with 1 or 2 substituents each of which is independently aryl or —C 1-6 alkyl substituted with aryl;
R 2 and R 3 are each independently —H or —C 1-6 alkyl;
R 5 is:
(1) —C 1-6 alkyl,
(2) —C 3-8 cycloalkyl optionally substituted with from 1 to 4 substituents each of which is independently —C 1-6 alkyl or —O—C 1-6 alkyl,
(3) —C 1-6 alkyl substituted with C 3-8 cycloalkyl, wherein the cycloalkyl is optionally substituted with from 1 to 4 substituents each of which is independently —C 1-6 alkyl or —O—C 1-6 alkyl,
(4) —C 1-6 alkyl substituted with aryl, wherein the aryl is optionally substituted with from 1 to 5 substituents each of which is independently —C 1-6 alkyl, —C 1-6 alkylene-O—C 1-6 alkyl, or halogen, or
(5) —C 1-6 alkyl substituted with a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein the heteroaromatic ring is optionally substituted with from 1 to 4 substituents each of which is independently —C 1-6 alkyl;
R V and R W are each independently —C 1-6 alkyl or R V and R W together with the N atom to which they are both attached form a 4- to 6-membered saturated heterocyclic ring optionally containing a heteroatom in addition to the nitrogen attached to R V and R W selected from N, O, and S, where the S is optionally oxidized to S(O) or S(O) 2 , and wherein the saturated heterocyclic ring is optionally substituted with 1 or 2 substituents each of which is independently a C 1-6 alkyl group;
each aryl is independently phenyl, naphthyl, or indenyl;
each R a is independently H or C 1-6 alkyl;
each R b is independently H or C 1-6 alkyl;
one of bonds
and
is a single bond and the other is a double bond; and
R T * is C 1-6 alkyl.
10. A process for preparing a compound of Formula VII:
which comprises reacting an alkylating agent of formula R 5 -Z with a compound of Formula VIII:
in a polar aprotic solvent and in the presence of a base selected from a magnesium base and a calcium base; wherein:
bond
in the ring is a single bond or a double bond;
W is —H or —C 1-6 alkyl;
Z is halogen or —SO 3 -Q wherein Q is (i) C 1-6 alkyl or (ii) phenyl optionally substituted with 1 or 2 substituents each of which is independently a C 1-6 alkyl;
R S is —O—C 1-6 alkyl or N(R V )R W wherein R V and R W are each independently —C 1-6 alkyl or R V and R W together with the N atom to which they are both attached form a 4- to 6-membered saturated heterocyclic ring optionally containing a heteroatom in addition to the nitrogen attached to R V and R W selected from N, O, and S, where the S is optionally oxidized to S(O) or S(O) 2 , and wherein the saturated heterocyclic ring is optionally substituted with 1 or 2 substituents each of which is independently a C 1-6 alkyl group;
R 1 is —C 1-6 alkyl substituted with R J , wherein R J is:
(A) aryl or aryl fused to a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein the aryl or fused aryl is:
(a) optionally substituted with from 1 to 5 substituents each of which is independently:
(1) —C 1-6 alkyl optionally substituted with —OH, —O—C 1-6 alkyl, —O—C 1-6 haloalkyl, —CN, —NO 2 , —N(R a )R b , —C(═O)N(R a )R b , —C(═O)R a , —CO 2 R a , —S(O) n R a , —SO 2 N(R a )R b , —N(R a )C(═O)R b , —N(R a )CO 2 R b , —N(R a )SO 2 R b , —N(R a )SO 2 N(R a )R b , —OC(═O)N(R a )R b , or —N(R a )C(═O)N(R a )R b ,
(2) —O—C 1-6 alkyl,
(3) —C 1-6 haloalkyl,
(4) —O—C 1-6 haloalkyl,
(5) —OH,
(6) halogen,
(7) —CN,
(8) —NO 2 ,
(9) —N(R a )R b ,
(10) —C(═O)N(R a )R b ,
(11) —C(═O)R a ,
(12) —CO 2 R a ,
(13) —SR a ,
(14) —S(═O)R a ,
(15) —SO 2 R a ,
(16) —SO 2 N(R a )R b ,
(17) —N(R a )SO 2 R b ,
(18) —N(R a )SO 2 N(R a )R b ,
(19) —N(R a )C(═O)R b ,
(20) —N(R a )C(═O)—C(═O)N(R a )R b , or
(21) —N(R a )CO 2 R b , and
(b) optionally substituted with 1 or 2 substituents each of which is independently:
(1) phenyl,
(2) benzyl,
(3) —HetA,
(4) —C(═O)—HetA, or
(5) —HetB;
wherein each HetA is independently a C 4-7 azacycloalkyl or a C 3-6 diazacycloalkyl, either of which is optionally substituted with from 1 to 4 substituents each of which is independently oxo or C 1-6 alkyl; and
wherein each HetB is a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein the heteroaromatic ring is optionally substituted with from 1 to 4 substituents each of which is independently halogen, —C 1-6 alkyl, —C 1-6 haloalkyl, —O—C 1-6 alkyl, —O—C 1-6 haloalkyl, or hydroxy; or
(B) a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S; wherein the heteroaromatic ring is
(i) optionally substituted with from 1 to 4 substituents each of which is independently halogen, —C 1-6 alkyl, —C 1-6 haloalkyl, —O—C 1-6 alkyl, —O—C 1-6 haloalkyl, or hydroxy, and
(ii) optionally substituted with 1 or 2 substituents each of which is independently aryl or —C 1-6 alkyl substituted with aryl;
R 2 and R 3 are each independently —H or —C 1-6 alkyl;
R 5 is:
(1) —C 1-6 alkyl,
(2) —C 3-8 cycloalkyl optionally substituted with from 1 to 4 substituents each of which is independently —C 1-6 alkyl or —O—C 1-6 alkyl,
(3) —C 1-6 alkyl substituted with C 3-8 cycloalkyl, wherein the cycloalkyl is optionally substituted with from 1 to 4 substituents each of which is independently —C 1-6 alkyl or —O—C 1-6 alkyl,
(4) —C 1-6 alkyl substituted with aryl, wherein the aryl is optionally substituted with from 1 to 5 substituents each of which is independently —C 1-6 alkyl, —C 1-6 alkylene-O—C 1-6 alkyl, or halogen, or
(5) —C 1-6 alkyl substituted with a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein the heteroaromatic ring is optionally substituted with from 1 to 4 substituents each of which is independently —C 1-6 alkyl;
each aryl is independently phenyl, naphthyl, or indenyl;
each R a is independently H or C 1-6 alkyl;
each R b is independently H or C 1-6 alkyl; and
each n is independently an integer equal to zero, 1, or 2.
11. A compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:
methyl 6-(4-fluorobenzyl)-4-hydroxy-3, 5-dioxo-2 , 3,5,6,7, 8-hexahydro-2,6-naphthyridine- 1 -carboxylate;
6-(4-fluorobenzyl)-4-hydroxy-N,N-dimethyl-3 ,5 -dioxo-2,3 ,5 ,6,7,8-hexahydro-2,6-naphthyridine- 1 -carboxamide;
N-cyclobutyl-6-(4-fluorobenzyl)-4-hydroxy-3 ,5 -dioxo-2,3 ,5 ,6,7,8-hexahydro-2,6-naphthyridine- 1 -carboxamide;
N-cyclopropyl-6-(4-fluorobenzyl)-4-hydroxy-3 ,5 -dioxo-2,3 ,5 ,6,7,8-hexahydro-2,6-naphthyridine- 1 -carboxamide;
6-(4-fluorobenzyl)-4-hydroxy-N-isopropyl-3 ,5 -dioxo-2,3 ,5 ,6,7,8-hexahydro-2,6-naphthyridine- 1 -carboxamide;
6-(4-fluorobenzyl)-4-hydroxy-N-methyl-3 ,5 -dioxo-2,3 ,5 ,6,7,8 -hexahydro-2,6-naphthyridine- 1 -carboxamide;
6-(4-fluorobenzyl)-4-hydroxy-3, 5 -dioxo-2,3 ,5 ,6,7, 8-hexahydro-2,6-naphthyridine- 1 -carboxylic acid;
N- [6-(4-fluorobenzyl)-3 ,4-dihydroxy-5 -oxo-5 ,6,7, 8-tetrahydro-2,6-naphthyridin-1 -yl]-N-methylmethanesulfonamide;
N- [6-(4-fluorobenzyl)-4-hydroxy-2-methyl-3 ,5 -dioxo-2,3 ,5 ,6,7, 8-hexahydro-2,6-naphthyridin- 1 -yl]-N-methylacetamide;
6-(4-fluorobenzyl)-4-hydroxy-N, N, 2-trimethyl-3,5-dioxo-2 , 3,5,6,7, 8-hexahydro-2,6-naphthyridine- 1 -carboxamide;
6-(3 -chloro-4-fluorobenzyl)-4-hydroxy-N,N,2-trimethyl-3 ,5 -dioxo-2,3 ,5 ,6,7, 8-hexahydro-2,6-naphthyridine- 1 -carboxamide; and
6-(4-fluorobenzyl)-4-hydroxy-N,N,2-trimethyl-3 ,5 -dioxo-2,3 ,5 ,6-tetrahydro-2,6-naphthyridine- 1 -carboxamide.